Single-dose cure for malaria edges closer to the clinic

MMV’s lead contender for a single-dose cure for malaria and artemisinin-resistant parasites enters Phase II clinical trials.

08 Feb 2011

8 February 2011, Geneva. A novel synthetic peroxide antimalarial drug candidate, OZ439 has successfully completed Phase 1 clinical trials where it was shown to be safe. It has progressed to trials in malaria patients. The secrets of OZ439’s success have been published today in Proceedings of the National Academy of Sciences.

This exciting compound is being developed by Medicines for Malaria Venture (MMV) in partnership with three academic institutes: University of Nebraska Medical Center, USA, Monash University, Victoria, Australia, and the Swiss Tropical and Public Health Institute.

OZ439 offers more than a convenient treatment advance. With the threat of artemisinin resistance and its potential to jeopardize recent wins in malaria control, fully synthetic peroxides, such as OZ439, could provide the urgently needed alternative.

“OZ439 holds a great deal of promise to power the eradication of malaria as it fits the bill on the two most crucial features of the ideal medicine: the potential for a one-dose cure and a treatment for artemisinin-resistant strains. If the clinical development proceeds as planned we can expect to see a new combination medicine launched by 2016. This will be a great day for malaria treatment and a real credit to the power of partnerships,” said Tim Wells, MMV’s Chief Scientific Officer.

Download the press release. [PDF: 35Kb]

View the open access article on the PNAS website: Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.